Clinigen, the global specialist pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This appointment strengthens the Board and ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety and promising objective response rates in patients with few treatment choices ...

Hyderabad based vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed a potential vaccine candidate for ...

Bharat Biotech and GSK collaborate to develop a vaccine for Shigellosis, a severe form of bacterial diarrhea. The innovative ...

Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and manufacturing, announced on Thursday that it has partnered with GSK plc, a global biopharma company, for the ...

Bharat Biotech joins GSK to develop a Shigella vaccine to fight shigellosis in children, with Phase 3 trials underway and ...

Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by ...

Shares of GSK PLC GSK inched up 0.96% to £15.23 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.13% to 8,864.35. GSK ...

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...

GSK said it licensed its Shigella vaccine candidate, altaltSonflex1-2-3, to Bharat Biotech International.

The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates ...